These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 16166795)

  • 1. Combined interferon and ribavirin therapy for chronic hepatitis C in Taiwan.
    Lai MY
    Intervirology; 2006; 49(1-2):91-5. PubMed ID: 16166795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
    Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
    Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current status of hepatitis C virus infection in Korea.
    Suh DJ; Jeong SH
    Intervirology; 2006; 49(1-2):70-5. PubMed ID: 16166792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
    Chuang WL; Dai CY; Chang WY; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
    Antivir Ther; 2005; 10(1):125-33. PubMed ID: 15751770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C.
    Arase Y; Ikeda K; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Koyama R; Hosaka T; Sezaki H; Kobayashi M; Kumada H
    Intervirology; 2007; 50(1):16-23. PubMed ID: 17164553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of hepatocellular carcinoma after interferon therapy in chronic hepatitis C. Is it possible to reduce the incidence by ribanirin and IFN combination therapy?
    Izumi N; Yasuhiro A; Kurosaki M; Onuki Y; Nishimura Y; Inoue K; Ueda K; Tsuchiya K; Nakanishi H; Uchihara M; Miyake S
    Intervirology; 2005; 48(1):59-63. PubMed ID: 15785091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
    Shindo M; Ken A; Okuno T
    Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prevalence and clinical characteristics of coinfection of SENV-H among Taiwanese chronic hepatitis C patients with combination therapy of high-dose interferon-alfa and ribavirin.
    Dai CY; Chuang WL; Chang WY; Chen SC; Lee LP; Lin ZY; Hou NJ; Hsieh MY; Wang LY; Yu ML
    Antiviral Res; 2004 Oct; 64(1):47-53. PubMed ID: 15451178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients.
    Giannini EG; Basso M; Savarino V; Picciotto A
    Aliment Pharmacol Ther; 2010 Feb; 31(4):502-8. PubMed ID: 19925499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
    Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
    Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy.
    Oze T; Hiramatsu N; Yakushijin T; Miyazaki M; Yamada A; Oshita M; Hagiwara H; Mita E; Ito T; Fukui H; Inui Y; Hijioka T; Inada M; Katayama K; Tamura S; Yoshihara H; Inoue A; Imai Y; Hayashi E; Kato M; Miyagi T; Yoshida Y; Tatsumi T; Kasahara A; Hamasaki T; Hayashi N; Takehara T;
    Clin Gastroenterol Hepatol; 2014 Jul; 12(7):1186-95. PubMed ID: 24321207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re-treatment of children with chronic hepatitis C who did not respond to interferon-alpha treatment.
    Gerner P; Hilbich J; Wenzl TG; Behrens R; Walther F; Kliemann G; Enninger A; Wirth S
    J Pediatr Gastroenterol Nutr; 2010 Aug; 51(2):187-90. PubMed ID: 20512050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A severe hepatitis flare in an HBV-HCV coinfected patient during combination therapy with alpha-interferon and ribavirin.
    Yalcin K; Degertekin H; Yildiz F; Kilinc N
    J Gastroenterol; 2003; 38(8):796-800. PubMed ID: 14505137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential changes of hepatitis C virus antibody profiles during treatment of chronic hepatitis C of genotype 1b: pretreatment antibody response to E2/NS1 correlated sustained response.
    Chu CM; Sheen IS; Liaw YF
    Infection; 2004 Jun; 32(3):153-6. PubMed ID: 15188075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viral etiology of hepatocellular carcinoma and HCV genotypes in Taiwan.
    Lee CM; Hung CH; Lu SN; Wang JH; Tung HD; Huang WS; Chen CL; Chen WJ; Changchien CS
    Intervirology; 2006; 49(1-2):76-81. PubMed ID: 16166793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term interferon monotherapy reduces the risk of HCV-associated hepatocellular carcinoma.
    Takeyasu M; Akuta N; Suzuki F; Seko Y; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2012 Aug; 84(8):1199-207. PubMed ID: 22711347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of interferon alpha with ribavirin for treatment of chronic Hepatitis C].
    Tao J; Liu J; Pu D; Lei H
    Zhonghua Gan Zang Bing Za Zhi; 2011 Sep; 19(9):683-5. PubMed ID: 22152384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon therapy for 2 years or longer reduces the incidence of hepatocarcinogenesis in patients with chronic hepatitis C viral infection.
    Arase Y; Ikeda K; Tsubota A; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Hosaka T; Sezaki H; Kobayashi M; Kumada H
    Intervirology; 2004; 47(6):355-61. PubMed ID: 15564748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C.
    Mousa DH; Abdalla AH; Al-Shoail G; Al-Sulaiman MH; Al-Hawas FA; Al-Khader AA
    Transplant Proc; 2004; 36(6):1831-4. PubMed ID: 15350490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.